Progression of hemolysis in a patient with hereditary spherocytosis after the second dose of COVID-19 mRNA vaccine

Herein, we report the case of a 22-year-old woman with hereditary spherocytosis (HS) whose condition worsened after administration of the coronavirus disease 2019 (COVID-19), mRNA vaccine ‘BNT162b2 Pfizer-BioNTech.’ The woman had been diagnosed with HS in 2005, and her condition remained stable unti...

Descripción completa

Detalles Bibliográficos
Autores principales: Nomura, Jun, Seki, Masafumi, Abe, Syori, Kobayashi, Tadahiro, Okitsu, Yoko, Fukuhara, Noriko, Takahashi, Shinichiro, Harigae, Hideo, Kameoka, Junichi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Taylor & Francis 2023
Materias:
Coronavirus
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10012938/
https://www.ncbi.nlm.nih.gov/pubmed/36625832
http://dx.doi.org/10.1080/21645515.2023.2165381
_version_ 1784906711452090368
author Nomura, Jun
Seki, Masafumi
Abe, Syori
Kobayashi, Tadahiro
Okitsu, Yoko
Fukuhara, Noriko
Takahashi, Shinichiro
Harigae, Hideo
Kameoka, Junichi
author_facet Nomura, Jun
Seki, Masafumi
Abe, Syori
Kobayashi, Tadahiro
Okitsu, Yoko
Fukuhara, Noriko
Takahashi, Shinichiro
Harigae, Hideo
Kameoka, Junichi
author_sort Nomura, Jun
collection PubMed
description Herein, we report the case of a 22-year-old woman with hereditary spherocytosis (HS) whose condition worsened after administration of the coronavirus disease 2019 (COVID-19), mRNA vaccine ‘BNT162b2 Pfizer-BioNTech.’ The woman had been diagnosed with HS in 2005, and her condition remained stable until February 2021. In March 2021, she received the first dose of the above vaccine and experienced pain at the injection site. After the second dose in April 2021, she developed fever and general malaise. Investigations revealed progression of hemolysis, which improved after a few days. To the best of our knowledge, this is the first report of progression of hemolysis in a patient with HS after administration of the mRNA vaccine COVID-19, BNT162b2 ‘Pfizer-BioNTech.’
format Online
Article
Text
id pubmed-10012938
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Taylor & Francis
record_format MEDLINE/PubMed
spelling pubmed-100129382023-03-15 Progression of hemolysis in a patient with hereditary spherocytosis after the second dose of COVID-19 mRNA vaccine Nomura, Jun Seki, Masafumi Abe, Syori Kobayashi, Tadahiro Okitsu, Yoko Fukuhara, Noriko Takahashi, Shinichiro Harigae, Hideo Kameoka, Junichi Hum Vaccin Immunother Coronavirus Herein, we report the case of a 22-year-old woman with hereditary spherocytosis (HS) whose condition worsened after administration of the coronavirus disease 2019 (COVID-19), mRNA vaccine ‘BNT162b2 Pfizer-BioNTech.’ The woman had been diagnosed with HS in 2005, and her condition remained stable until February 2021. In March 2021, she received the first dose of the above vaccine and experienced pain at the injection site. After the second dose in April 2021, she developed fever and general malaise. Investigations revealed progression of hemolysis, which improved after a few days. To the best of our knowledge, this is the first report of progression of hemolysis in a patient with HS after administration of the mRNA vaccine COVID-19, BNT162b2 ‘Pfizer-BioNTech.’ Taylor & Francis 2023-01-10 /pmc/articles/PMC10012938/ /pubmed/36625832 http://dx.doi.org/10.1080/21645515.2023.2165381 Text en © 2023 The Author(s). Published with license by Taylor & Francis Group, LLC. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives License (http://creativecommons.org/licenses/by-nc-nd/4.0/ (https://creativecommons.org/licenses/by-nc-nd/4.0/) ), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited, and is not altered, transformed, or built upon in any way.
spellingShingle Coronavirus
Nomura, Jun
Seki, Masafumi
Abe, Syori
Kobayashi, Tadahiro
Okitsu, Yoko
Fukuhara, Noriko
Takahashi, Shinichiro
Harigae, Hideo
Kameoka, Junichi
Progression of hemolysis in a patient with hereditary spherocytosis after the second dose of COVID-19 mRNA vaccine
title Progression of hemolysis in a patient with hereditary spherocytosis after the second dose of COVID-19 mRNA vaccine
title_full Progression of hemolysis in a patient with hereditary spherocytosis after the second dose of COVID-19 mRNA vaccine
title_fullStr Progression of hemolysis in a patient with hereditary spherocytosis after the second dose of COVID-19 mRNA vaccine
title_full_unstemmed Progression of hemolysis in a patient with hereditary spherocytosis after the second dose of COVID-19 mRNA vaccine
title_short Progression of hemolysis in a patient with hereditary spherocytosis after the second dose of COVID-19 mRNA vaccine
title_sort progression of hemolysis in a patient with hereditary spherocytosis after the second dose of covid-19 mrna vaccine
topic Coronavirus
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10012938/
https://www.ncbi.nlm.nih.gov/pubmed/36625832
http://dx.doi.org/10.1080/21645515.2023.2165381
work_keys_str_mv AT nomurajun progressionofhemolysisinapatientwithhereditaryspherocytosisaftertheseconddoseofcovid19mrnavaccine
AT sekimasafumi progressionofhemolysisinapatientwithhereditaryspherocytosisaftertheseconddoseofcovid19mrnavaccine
AT abesyori progressionofhemolysisinapatientwithhereditaryspherocytosisaftertheseconddoseofcovid19mrnavaccine
AT kobayashitadahiro progressionofhemolysisinapatientwithhereditaryspherocytosisaftertheseconddoseofcovid19mrnavaccine
AT okitsuyoko progressionofhemolysisinapatientwithhereditaryspherocytosisaftertheseconddoseofcovid19mrnavaccine
AT fukuharanoriko progressionofhemolysisinapatientwithhereditaryspherocytosisaftertheseconddoseofcovid19mrnavaccine
AT takahashishinichiro progressionofhemolysisinapatientwithhereditaryspherocytosisaftertheseconddoseofcovid19mrnavaccine
AT harigaehideo progressionofhemolysisinapatientwithhereditaryspherocytosisaftertheseconddoseofcovid19mrnavaccine
AT kameokajunichi progressionofhemolysisinapatientwithhereditaryspherocytosisaftertheseconddoseofcovid19mrnavaccine

Ejemplares similares